Search results
Results from the WOW.Com Content Network
Infliximab is indicated for steroid refractory checkpoint inhibitor induced colitis, at a dose of 5 to 10 mg/kg. [41] Infliximab has been found to be a safe alternative treatment to a second dose of IVIG for Kawasaki Disease resistant to initial IVIG therapy, showing better outcomes in fever resolution and fewer severe adverse effects such as ...
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
The World Association of Sarcoidosis and other Granulomatous Disorders, also known as WASOG is an organisation of physicians involved in the diagnosis and treatment of sarcoidosis and related conditions.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Sarcoidosis may resolve without any treatment within a few years. [2] [5] However, some people may have long-term or severe disease. [5] Some symptoms may be improved with the use of anti-inflammatory drugs such as ibuprofen. [8] In cases where the condition causes significant health problems, steroids such as prednisone are indicated. [9]
A combination of azathioprine and infliximab treatment may be more effective than a single dose of infliximab to induce steroid-free remission for people with active Crohn's disease. [9] Azathioprine treatment may lead to rare but life-threatening side effects. The rare side effects include leukopenia or pancreatitis. [9]
If this is effective, the dose may gradually be reduced (although many patients need to remain on steroids long-term, frequently leading to side-effects such as diabetes or osteoporosis). Methotrexate , hydroxychloroquine , cyclophosphamide , pentoxifylline , thalidomide and infliximab have been reported to be effective in small studies.
They are used in the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriasis. These drugs may raise the risk of contracting tuberculosis or inducing a latent infection to become active. Infliximab and adalimumab have label warnings stating that patients should be evaluated for latent TB infection and treatment ...